Stellar second quarter sign of things to come at Pfizer

28 July 2021
pfizer_big

Pfizer’s (NYSE: PFE) investment in developing a novel coronavirus vaccine has paid off, and then some, the firm’s second-quarter results statement reveals.

The company brought in $7.8 billion from sales of the mRNA-based shot, more than twice the amount generated in the first three months of the year.

In total, the company now expects to bring in a vertiginous $33.5 billion in 2021 from sales of BNT162b2, known as Comirnaty in Europe, up from an earlier estimate of $26 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology